Chemosensory receptor ligand-based therapies
Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
1. A method of lowering blood glucose levels in a subject in need thereof, comprising administering to said subject a composition comprising metformin or a salt thereof, wherein said composition is adapted to release a therapeutically effective amount of metformin downstream of the stomach, to one or more regions of the intestine.
2. A method of treating disorders of glucose metabolism in a subject in need thereof, comprising administering to said subject a composition comprising metformin or a salt thereof, wherein said composition is adapted to release a therapeutically effective amount of metformin downstream of the stomach, to one or more regions of the intestine.
3. The method according to claim 2 , wherein said disorder is hyperglycemia.
4. A method of treating a condition associated with a chemosensory receptor in a subject in need thereof comprising administering to said subject a composition comprising metformin or a salt thereof, wherein said composition is adapted to release a therapeutically effective amount of metformin downstream of the stomach, to one or more regions of the intestine, wherein said condition associated with a chemosensory receptor is selected from diabetes, prediabetes, and obesity.
5. The method according to any one of claims 1 - 4 , wherein said metformin salt is metformin hydrochloride.
6. The method according to any one of claims 1 - 4 , wherein said one or more regions of the intestine are the duodenum, jejunum, ileum and/or lower intestine.
7. The method according to any one of claims 1 - 4 , wherein said one or more regions of the intestine are the jejunum, ileum and/or lower intestine.
8. The method according to any one of claims 1 - 4 , wherein said composition releases metformin at an onset of about pH 5.0, about pH 5.5, about pH 6.0, about pH 6.5, about pH 7.0, or combination thereof following administration to a subject.
9. The method according to any one of claims 1 - 4 , wherein said therapeutically effective amount of metformin or salt thereof is about 1 mg to about 2000 mg.
10. The method according to any one of claims 1 - 4 , wherein said therapeutically effective amount of metformin or salt thereof is about 50 mg to about 1000 mg.
11. The method according to any one of claims 1 - 4 , wherein said composition further comprises a second antidiabetic agent or an antiobesity agent.
12. The method according to claim 11 , wherein said second antidiabetic agent is selected from the group consisting of thiazolidinediones, sulfonyureas, meglitinides, alpha-glucosidase inhibitors, DPP-IV inhibitors, and incretin mimetics, and SGLT inhibitors.
13. The method according to claim 11 , wherein said antiobesity agent is selected from the group consisting of phentermine, fenfluramine, sibutramine, rimonabant, topiramate, zonisamide bupropion, naltrexone, lorcaserin, and orlistat.
14. The method according to any one of claims 1 - 4 , said composition further comprising a chemosensory receptor ligand selected from the group consisting of a sweet receptor ligand, a bitter receptor ligand, an umami receptor ligand, a fat receptor ligand, a sour receptor ligand and a bile acid receptor ligand.
15. The method according to claim 4 , wherein said condition is diabetes or pre-diabetes.
16. The method according to claim 4 , wherein said condition is obesity.
17. The method according to any one of claims 1 - 4 , wherein the circulating hormone levels of GLP-1 and/or PYY are increased as compared to circulating hormone levels with a placebo composition.
18. The method according to claim 15 , wherein said composition further comprises a second antidiabetic agent.
19. The method according to claim 18 , wherein said second antidiabetic agent is selected from the group consisting of thiazolidinediones, sulfonyureas, meglitinides, alpha-glucosidase inhibitors, DPP-IV inhibitors, incretin mimetics, and SGLT inhibitors.
20. The method according to claim 16 , wherein said composition further comprises an antiobesity agent.
21. The method according to claim 20 , wherein said antiobesity agent is selected from the group consisting of phentermine, fenfluramine, sibutramine, rimonabant, topiramate, zonisamide bupropion, naltrexone, lorcaserin, and orlistat.
22. The method according to any one of claims 1 - 4 , wherein said composition is adapted to release a therapeutically effective amount of metformin downstream of the duodenum.
23. The method according to any one of claims 1 - 4 , wherein said composition is adapted to release a therapeutically effective amount of metformin downstream of the jejunum.
24. The method according to any one of claims 1 - 4 , wherein said one or more regions of the intestine are the ileum and/or lower intestine.
25. The method according to any one of claims 1 - 4 , wherein said composition further releases about 10% of said metformin in the stomach.